Priority Health Medicare prior authorization form

Fax completed form to: 877.974.4411 toll free, or 616.942.8206

This form applies to: ☐ **Medicare Part B** ☒ **Medicare Part D**

This request is: ☐ **Expedited request** ☐ **Standard request**

Your request will be expedited if you haven't gotten the prescription and Priority Health Medicare determines, or your prescriber tells us, that your life or health may be at risk by waiting.

Rydapt™ (midostaurin)

Member

Last Name: _____ First Name: _____

ID #: _____ DOB: _____ Gender: _____

Primary Care Physician: _____

Requesting Provider: _____ Prov. Phone: _____ Prov. Fax: _____

Provider Address: _____

Provider NPI: _____ Contact Name: _____

Provider Signature: _____ Date: _____

Drug information

☐ New request ☐ Continuation request

Drug Product: ☐ Rydapt 25 mg capsule

Start date (or date of next dose): _____

Date of last dose (if applicable): _____

Dosing frequency: _____

Prior authorization criteria

The following requirements need to be met before this drug is covered by Priority Health Medicare. These requirements have been approved by the Centers for Medicare and Medicaid Services (CMS), but you may ask us for an exception if you believe one or more of these requirements should be waived.

1. Must be 18 years or older
2. The patient must have one of the following diagnoses and meet any required criteria:
   - Advanced systemic mastocytosis including aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL)
   - Acute myeloid leukemia (AML) that meets all of the following:
     - Newly diagnosed
     - FLT3 mutation-positive disease as detected by an FDA-approved test
     - Must use Rydapt in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy

Additional information

Note: If approved, coverage is provided for 1 year. For AML, Rydapt is limited to 6 cycles.

Medically accepted indication

This drug is only covered under Medicare Part D when it is used for a medically accepted indication. A medically accepted indication is a use of the drug that is *either*:

- approved by the Food and Drug Administration. (That is, the Food and Drug Administration has approved the drug for the diagnosis or condition for which it is being prescribed.)
- — *or* — supported by certain reference books. (These reference books are the American Hospital Formulary Service Drug Information and the DRUGDEX Information System)

All fields must be complete and legible for review. Your office will receive a response via fax.

Updated 01/2018
Last reviewed 01/2019

New request
Priority Health Precertification Documentation

A. What condition is this drug being requested for?

- ☐ Acute myeloid leukemia
- ☐ Advanced systemic mastocytosis
  - ☐ Aggressive systemic mastocytosis (ASM)
  - ☐ Systemic mastocytosis with associated hematological neoplasm (SM-AHN)
  - ☐ Mast cell leukemia (MCL)
- ☐ *Other – the patient's condition is:* _____

For Acute Myeloid Leukemia (AML)

A. Is the patient newly diagnosed?

- ☐ Yes
- ☐ No. *Rationale for use:* _____

B. Does the patient have FLT3 mutation-positive disease as detected by an FDA-approved test?

- ☐ Yes
- ☐ No. *Rationale for use:* _____

C. Is Rydapt being used in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy?

- ☐ Yes
- ☐ No. *Rationale for use:* _____

Priority Health Medicare exception request

Do you believe one or more of the prior authorization requirements should be waived? ☐ Yes ☐ No
If yes, you must provide a statement explaining the medical reason why the exception should be approved.

Would Rydapt likely be the most effective option for this patient?

- ☐ No
- ☐ Yes, because: _____

_____

If the patient is currently using Rydapt, would changing the patient's current regimen likely result in adverse effects for the patient?

- ☐ No
- ☐ Yes, because: _____

_____

All fields must be complete and legible for review. Your office will receive a response via fax.
Updated 01/2018
Last reviewed 01/2019